Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kilometro Rosso Spa currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, MCCOLLUM, ANDREA K, who is the busiest examiner with 1 pending office action. The portfolio is currently active in 1 distinct art unit, indicating a focused approach to patenting in this sector.
The 1 pending office action represents the total current workload for the company at the USPTO. Because MCCOLLUM, ANDREA K is the only examiner, the company's prosecution results are currently tied to this 1 individual. The use of 1 distinct art unit suggests that the underlying technology fits within a specific biotechnological niche.
This concentration simplifies the management of the portfolio, as there are no competing deadlines or varying examiner styles to navigate. Practitioners should note that the outcome of this single office action will define the immediate success rate for the portfolio. The alignment of the examiner and art unit allows the legal team to focus exclusively on the specific preferences of MCCOLLUM, ANDREA K.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCCOLLUM, ANDREA K | 1 | 60.7% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556691 | FUSION PROTEINS AND USE THEREOF IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY | MCCOLLUM, ANDREA K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556691 | FUSION PROTEINS AND USE THEREOF IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY | MCCOLLUM, ANDREA K | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556691 | FUSION PROTEINS AND USE THEREOF IN THE TREATMENT OF MEMBRANOUS NEPHROPATHY | MCCOLLUM, ANDREA K | 1674 | §103§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial